Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer.

However, when either si DUT or CV6-530 was combined with FUdR, highly significant decreases in cell proliferation and survival compared to single-agent FUdR were observed across all FUdR concentrations (Fig. 1A–F ).

also in 132,142 other papers